Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Why Idera Pharmaceuticals
Soared 20% In September
What:
• The clinical-stage biotech company is studying two drugs.
– IMO 8400 for B-cell lymphomas.
– IMO 9200 for autoimmu...
Idera Pharmaceuticals
So what:
• Under development to treat Waldenstrom’s and diffuse
B-cell lymphoma with an amenable genetic mutation.
– Could...
Now what:
• WM phase 2 data coming this quarter.
– Mid stage results could be encouraging, but a phase 3
trial still needs...
Now what continued:
• Cash totals $106.3 million exiting Q2.
– Operating expenses totaled $12.8 million last quarter.
– Ex...
Leaked: The next
billion-dollar iSecret
Upcoming SlideShare
Loading in …5
×

Why Idera Pharmaceuticals Soared 20% In September

3,482 views

Published on

Idera Pharmaceuticals (NASDAQ: IDRA) bucked the biotech sell-off last month by gaining more than 20%. The company, which currently doesn't have any products on the market, is working on intriguing new cancer therapies for patients with specific genetic mutations. Idera Pharmaceuticals approach is intriguing and investors should soon know whether its most advanced drug, IMO 8400, is effective in at least one rare form of cancer. View the slideshow to learn more about Idera Pharmaceuticals and what's driving interest in its shares.

Published in: Healthcare
  • Follow the link, new dating source: ♥♥♥ http://bit.ly/36cXjBY ♥♥♥
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
  • Dating for everyone is here: ❤❤❤ http://bit.ly/36cXjBY ❤❤❤
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
  • Be the first to like this

Why Idera Pharmaceuticals Soared 20% In September

  1. 1. Why Idera Pharmaceuticals Soared 20% In September
  2. 2. What: • The clinical-stage biotech company is studying two drugs. – IMO 8400 for B-cell lymphomas. – IMO 9200 for autoimmune disease. • Data should be released on IMO 8400 in Q4. – Results from its phase 2 Waldenstrom’s macroglobulinemia trial. • Shares jumped 20.1% in September.
  3. 3. Idera Pharmaceuticals
  4. 4. So what: • Under development to treat Waldenstrom’s and diffuse B-cell lymphoma with an amenable genetic mutation. – Could benefit up to 90% of 1,200 new WM cases annually. – Could treat up to 30% of the 2,000 new diffuse B-cell lymphoma cases annually.
  5. 5. Now what: • WM phase 2 data coming this quarter. – Mid stage results could be encouraging, but a phase 3 trial still needs to occur. • Diffuse B-cell lymphoma data expected next year. – Potential therapy for pre-treated patients would be welcome, but too early to gauge whether this one will be a success.
  6. 6. Now what continued: • Cash totals $106.3 million exiting Q2. – Operating expenses totaled $12.8 million last quarter. – Expanding trials will increase cash burn in the coming year. • High-risk/high-reward play suitable only for aggressive investors. – Keep an eye out for upcoming WM data.
  7. 7. Leaked: The next billion-dollar iSecret

×